Prognostic impact of the acute reactiveness to intravenous administration of tolvaptan sodium phosphate in patients with acute decompensated heart failure. [PDF]
Eur Heart J OpenOuchi S +6 more
europepmc +1 more source
Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis. [PDF]
Cochrane Database Syst RevAnila KN +8 more
europepmc +1 more source
Ovarian hormones moderate systolic hypertension in female <i>Eln</i> haploinsufficient mice. [PDF]
Am J Physiol Renal PhysiolDixon AJ +4 more
europepmc +1 more source
Relcovaptan: a promising therapeutic agent in traumatic spinal cord injury that acts by modulating newly identified transcriptional regulators of aquaporins compared to tolvaptan. [PDF]
Turk J Med SciIş Ş +4 more
europepmc +1 more source
Poor compliance of recurrent stone formers to increase their fluid intake in spite of repeated recommendation. [PDF]
Clin Kidney JBankir L, Daudon M.
europepmc +1 more source
Response to the Letter to the Editor Entitled "SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes". [PDF]
Kidney Int RepUchiyama K.
europepmc +1 more source
Related searches:
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
Jalal K, Ghali +3 more
openaire +2 more sources
Tolvaptan is an orally administered, nonpeptide, selective arginine vasopressin V(2) receptor antagonist that increases free water clearance, thereby correcting low serum sodium levels. SALT-1 and -2, two identical, randomized, double-blind, placebo-controlled, multicentre trials, included patients with hypervolaemic or euvolaemic hyponatraemia (serum ...
openaire +2 more sources